Race Oncology Update & Investor Presentation
Filed with ASX · · 18 pages · English
11 January 2016, San Francisco CA: Race Oncology Ltd (ASX: RAC) announced today that it had released an updated investor presentation that was shared with investors at a function this week in San Francisco, California, associated with the JP Morgan Healthcare Conference. The presentation is available on the company’s website at www.raceoncology.com. “The JP Morgan conference is the premier annual
Earlier from Racura Oncology
- Race Signs Agreement with US Based IriSys LLC
- Race Signs Key Manufacturing Agreement for Bisantrene
- Race Signs NPP Partnership with CarthaGenetics in Europe
- Race signs agreement with Camargo Pharmaceutical
- Race signs agreement with Crystal Pharmatech
Later from Racura Oncology
- Pre-IND Meeting Confirms 505(b)(2) Pathway for Bisantrene
- Bisantrene License Agreement for Korea
- Race Announces NCI Collaboration
- Race Joint Venture with TargImmune
- Race Completes Over-Subscribed $2.5 Million Placement
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology